• Immunogenicity and durability against Omicron BA.1 BA.2 and BA.4/5 variants at 3�months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination

  • Back
    bibtex

Document Title

Immunogenicity and durability against Omicron BA.1 BA.2 and BA.4/5 variants at 3�months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination

Author

Assawakosri S. Kanokudom S. Suntronwong N. Chansaenroj J. Auphimai C. Nilyanimit P. Vichaiwattana P. Thongmee T. Duangchinda T. Chantima W. Pakchotanon P. Srimuan D. Thatsanathorn T. Klinfueng S. Sudhinaraset N. Wanlapakorn N. Mongkolsapaya J. Honsawek S. Poovorawan Y.

Affiliations

Center of Excellence in Clinical Virology Faculty of Medicine Chulalongkorn University Bangkok 10330 Thailand; Center of Excellence in Osteoarthritis and Musculoskeleton Faculty of Medicine Chulalongkorn University King Chulalongkorn Memorial Hospital Thai Red Cross Society Bangkok 10330 Thailand; Molecular Biology of Dengue and Flaviviruses Research Team National Center for Genetic Engineering and Biotechnology National Science and Development Agency NSTDA Pathum Thani 12120 Thailand; Division of Dengue Hemorrhagic Fever Research Faculty of Medicine Siriraj Hospital Mahidol University Bangkok 10700 Thailand; Siriraj Center of Research Excellence in Dengue and Emerging Pathogens Faculty of Medicine Siriraj Hospital Mahidol University Bangkok 10700 Thailand; Wellcome Centre for Human Genetics Nuffield Department of Medicine University of Oxford Oxford OX3 7BN United Kingdom; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI) University of Oxford Oxford United Kingdom; FRS(T) the Royal Society of Thailand Sanam Sueapa Dusit Bangkok 10330 Thailand

Type

Article

Source Title

Heliyon

ISSN

24058440

Year

2024

Volume

10

Issue

1

Open Access

All Open Access Gold Green

Publisher

Elsevier Ltd

DOI

10.1016/j.heliyon.2023.e23892

Abstract

Background: Several countries have authorized a booster vaccine campaign to combat the spread of COVID-19. Data on persistence of booster vaccine?induced immunity against new Omicron subvariants are still limited. Therefore our study aimed to determine the serological immune response of COVID-19 booster after CoronaVac-priming. Methods: A total of 187 CoronaVac-primed participants were enrolled and received an inactivated (BBIBP) viral vector (AZD1222) or mRNA vaccine (full-/half-dose BNT162B2 full-/half-dose mRNA-1273) as a booster dose. The persistence of humoral immunity both binding and neutralizing antibodies against wild-type and Omicron was determined on day 90�0 after booster. Results: A waning of total RBD immunoglobulin (Ig) levels anti-RBD IgG and neutralizing antibodies against Omicron BA.1 BA.2 and BA.4/5 variants was observed 90�0 days after booster vaccination. Participants who received mRNA-1273 had the highest persistence of the immunogenicity response followed by BNT162b2 AZD1222 and BBIBP-CorV. The responses between full and half doses of mRNA-1273 were comparable. The percentage reduction of binding antibody ranged from 50 % to 75 % among all booster vaccine. Conclusions: The antibody response substantially waned after 90�0 days post-booster dose. The heterologous mRNA and the viral vector booster demonstrated higher detectable rate of humoral immune responses against the Omicron variant compared to the inactivated BBIBP booster. Nevertheless an additional fourth dose is recommended to maintain immune response against infection. ? 2023 The Authors

License

CC BY

Rights

Authors

Publication Source

WOS

Continue browsing